Covid-19 Vaccine Pioneer BioNTech Plans to Make New Malaria and Tuberculosis Shots in Africa

BioNTech said it would invest some of the profits from the Covid-19 vaccine it markets with Pfizer into developing shots for malaria and tuberculosis in Africa, part of the company’s plan to establish a production hub for innovative medicines

BioNTech SE said it would invest some of the profits from the Covid-19 vaccine it markets with Pfizer Inc. into developing shots for malaria and tuberculosis in Africa, part of the German company’s plan to establish a large production hub for innovative medicines on the continent.

The company’s new venture aims to produce a highly effective mRNA vaccine with durable protective immunity to prevent and eventually eradicate malaria, he said.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

WSJ /  🏆 98. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

WSJ News Exclusive | Covid-19 Immunity Wanes, but Third Shot Still Rarely Needed, BioNTech CEO SaysCovid-19 immunity wanes in people fully vaccinated with the Pfizer-BioNTech shot, but most still won’t need a third dose, the CEO of BioNTech said
Read more »

Outbreaks of covid-19 leave South-East Asia with little policy roomOn July 20th the Asian Development Bank pared back its growth forecasts for South-­East Asia. It now expects an expansion of 4% this year, compared with an earlier forecast of 4.4%
Read more »

Leopardo de las nieves Ramil tiene COVID-19 en el Zoo de San DiegoEl personal del zoológico está investigando cómo se infectó
Read more »

Covid-19 Vaccine Holdouts Face Restrictions in Europe as Delta Variant SpreadsWorried about the rapid spread of the Delta variant, governments are nudging, and in some cases, pushing, people to get vaccinated by introducing restrictions to daily life for those without a Covid-19 shot.
Read more »

WSJ News Exclusive | Covid-19 Pill Race Heats Up as Japanese Firm Vies With Pfizer, MerckJapan’s Shionogi has started human trials for a once-a-day drug designed to neutralize the coronavirus in less than a week as Pfizer and Merck carry out later-stage tests.
Read more »